Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer

Charles Blanke, B. Kasimis, P. Schein, R. Capizzi, M. Kurman

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose: A phase II study to evaluate the response rate and toxicities of a trimetrexate, fluorouracil (5FU), and leucovorin regimen in patients with advanced incurable colorectal cancer. Patients and Methods: Thirty-six patients with unresectable or metastatic colorectal cancer who had not been treated for advanced disease received the following chemotherapy regimen weekly for six courses every 8 weeks: trimetrexate 110 mg/m2 intravenously (IV) an day 1, leucovorin 200 mg/m2 IV on day 2 (24 hours later), 5FU 500 mg/m2 on day 2 immediately following leucovorin, and oral leucovorin 15 mg every 6 hours for seven doses starting 6 hours after 5FU. Patients were treated until progression or unacceptable toxicity. Results: Thirty patients were assessable for response, and all 36 were assessable for toxicity. Two patients (7%) achieved a complete response (CR) and 13 (43%) a partial response (PR), for an overall response (OR) rate of 50% (95% confidence interval [CI], 32% to 68%). Analysis by intent to treat demonstrated a 42% OR rate (95% CI, 26% to 58%). At final analysis, 16 patients were alive. The median survival duration for the entire cohort was 53.4 weeks. Gastrointestinal toxicity was most common, with 21 patients (58%) having grade 3/4 diarrhea and 12 patients (34%) grade 3/4 nausea. Hematologic toxicity was generally low grade, although two patients died of sepsis. Conclusion: The combination of trimetrexate with 5FU and leucovorin is active in metastatic colorectal cancer. Gastrointestinal toxicity with this regimen is most prominent, but is manageable.

Original languageEnglish (US)
Pages (from-to)915-920
Number of pages6
JournalJournal of Clinical Oncology
Volume15
Issue number3
StatePublished - Mar 1997

Fingerprint

Trimetrexate
Leucovorin
Fluorouracil
Colorectal Neoplasms
Confidence Intervals
Nausea
Diarrhea
Sepsis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. / Blanke, Charles; Kasimis, B.; Schein, P.; Capizzi, R.; Kurman, M.

In: Journal of Clinical Oncology, Vol. 15, No. 3, 03.1997, p. 915-920.

Research output: Contribution to journalArticle

Blanke, C, Kasimis, B, Schein, P, Capizzi, R & Kurman, M 1997, 'Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer', Journal of Clinical Oncology, vol. 15, no. 3, pp. 915-920.
Blanke, Charles ; Kasimis, B. ; Schein, P. ; Capizzi, R. ; Kurman, M. / Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 3. pp. 915-920.
@article{fb1e54730fc04609a6c56b48818a77e6,
title = "Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer",
abstract = "Purpose: A phase II study to evaluate the response rate and toxicities of a trimetrexate, fluorouracil (5FU), and leucovorin regimen in patients with advanced incurable colorectal cancer. Patients and Methods: Thirty-six patients with unresectable or metastatic colorectal cancer who had not been treated for advanced disease received the following chemotherapy regimen weekly for six courses every 8 weeks: trimetrexate 110 mg/m2 intravenously (IV) an day 1, leucovorin 200 mg/m2 IV on day 2 (24 hours later), 5FU 500 mg/m2 on day 2 immediately following leucovorin, and oral leucovorin 15 mg every 6 hours for seven doses starting 6 hours after 5FU. Patients were treated until progression or unacceptable toxicity. Results: Thirty patients were assessable for response, and all 36 were assessable for toxicity. Two patients (7{\%}) achieved a complete response (CR) and 13 (43{\%}) a partial response (PR), for an overall response (OR) rate of 50{\%} (95{\%} confidence interval [CI], 32{\%} to 68{\%}). Analysis by intent to treat demonstrated a 42{\%} OR rate (95{\%} CI, 26{\%} to 58{\%}). At final analysis, 16 patients were alive. The median survival duration for the entire cohort was 53.4 weeks. Gastrointestinal toxicity was most common, with 21 patients (58{\%}) having grade 3/4 diarrhea and 12 patients (34{\%}) grade 3/4 nausea. Hematologic toxicity was generally low grade, although two patients died of sepsis. Conclusion: The combination of trimetrexate with 5FU and leucovorin is active in metastatic colorectal cancer. Gastrointestinal toxicity with this regimen is most prominent, but is manageable.",
author = "Charles Blanke and B. Kasimis and P. Schein and R. Capizzi and M. Kurman",
year = "1997",
month = "3",
language = "English (US)",
volume = "15",
pages = "915--920",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer

AU - Blanke, Charles

AU - Kasimis, B.

AU - Schein, P.

AU - Capizzi, R.

AU - Kurman, M.

PY - 1997/3

Y1 - 1997/3

N2 - Purpose: A phase II study to evaluate the response rate and toxicities of a trimetrexate, fluorouracil (5FU), and leucovorin regimen in patients with advanced incurable colorectal cancer. Patients and Methods: Thirty-six patients with unresectable or metastatic colorectal cancer who had not been treated for advanced disease received the following chemotherapy regimen weekly for six courses every 8 weeks: trimetrexate 110 mg/m2 intravenously (IV) an day 1, leucovorin 200 mg/m2 IV on day 2 (24 hours later), 5FU 500 mg/m2 on day 2 immediately following leucovorin, and oral leucovorin 15 mg every 6 hours for seven doses starting 6 hours after 5FU. Patients were treated until progression or unacceptable toxicity. Results: Thirty patients were assessable for response, and all 36 were assessable for toxicity. Two patients (7%) achieved a complete response (CR) and 13 (43%) a partial response (PR), for an overall response (OR) rate of 50% (95% confidence interval [CI], 32% to 68%). Analysis by intent to treat demonstrated a 42% OR rate (95% CI, 26% to 58%). At final analysis, 16 patients were alive. The median survival duration for the entire cohort was 53.4 weeks. Gastrointestinal toxicity was most common, with 21 patients (58%) having grade 3/4 diarrhea and 12 patients (34%) grade 3/4 nausea. Hematologic toxicity was generally low grade, although two patients died of sepsis. Conclusion: The combination of trimetrexate with 5FU and leucovorin is active in metastatic colorectal cancer. Gastrointestinal toxicity with this regimen is most prominent, but is manageable.

AB - Purpose: A phase II study to evaluate the response rate and toxicities of a trimetrexate, fluorouracil (5FU), and leucovorin regimen in patients with advanced incurable colorectal cancer. Patients and Methods: Thirty-six patients with unresectable or metastatic colorectal cancer who had not been treated for advanced disease received the following chemotherapy regimen weekly for six courses every 8 weeks: trimetrexate 110 mg/m2 intravenously (IV) an day 1, leucovorin 200 mg/m2 IV on day 2 (24 hours later), 5FU 500 mg/m2 on day 2 immediately following leucovorin, and oral leucovorin 15 mg every 6 hours for seven doses starting 6 hours after 5FU. Patients were treated until progression or unacceptable toxicity. Results: Thirty patients were assessable for response, and all 36 were assessable for toxicity. Two patients (7%) achieved a complete response (CR) and 13 (43%) a partial response (PR), for an overall response (OR) rate of 50% (95% confidence interval [CI], 32% to 68%). Analysis by intent to treat demonstrated a 42% OR rate (95% CI, 26% to 58%). At final analysis, 16 patients were alive. The median survival duration for the entire cohort was 53.4 weeks. Gastrointestinal toxicity was most common, with 21 patients (58%) having grade 3/4 diarrhea and 12 patients (34%) grade 3/4 nausea. Hematologic toxicity was generally low grade, although two patients died of sepsis. Conclusion: The combination of trimetrexate with 5FU and leucovorin is active in metastatic colorectal cancer. Gastrointestinal toxicity with this regimen is most prominent, but is manageable.

UR - http://www.scopus.com/inward/record.url?scp=0031056423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031056423&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 915

EP - 920

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -